Prevalence and socioeconomic determinants of financial toxicity in patients undergoing breast cancer surgery in Canada: A cross-sectional study.
Abstract
241 Background: Financial toxicity (FT) has now been established as a treatment-related harm in oncology, including among patients with breast cancer. However, the evidence base rests largely on data from the United States, where patient cost-sharing is substantial. Few studies have characterized FT in high-income, publicly funded healthcare systems. We present the first study examining breast cancer related FT in Canadian patients using a validated FT measurement instrument. Methods: Patients with non-metastatic breast cancer who underwent surgery at a tertiary cancer center completed the validated FACIT-COST questionnaire within 18 months of surgery. COST scores were graded as no FT (≥26), mild (14-25), moderate (1-13), or severe (0); any FT was defined as COST <26. Sociodemographic variables and out-of-pocket costs (OOPC) were self-reported; clinical data were abstracted from medical records. Patients with and without FT were compared using chi-square, Fisher's exact, and Wilcoxon rank-sum tests. Multivariable logistic regression estimated adjusted odds ratios (aOR) for independent predictors of any FT. Results: Of 155 patients, median age was 56 years (IQR 47-68). Most had stage I (n=79, 51.0%), with 30.3% (n=47) stage II and 8.4% (n=13) stage III. Annual household income was >$80,000 CAD in 50.3% (n=78), $40,000-80,000 in 27.1% (n=42), and <$40,000 in 16.8% (n=26); 45.8% (n=71) identified as racialized. No patient was uninsured. Any FT was present in 46.5% (95% CI 38.8-54.3): 27.7% (n=43) mild, 18.1% (n=28) moderate, and 0.6% (n=1) severe. OOPC were higher among patients with FT (median $2,000 [IQR $600-4,750] vs $500 [$100-2,000]; p<0.001). On bivariable analysis, racial and ethnic identity (p=0.003), birth outside Canada (p=0.001), single status (p=0.016), dependents at home (p=0.036), employment status (p=0.006), lower household income (p<0.001), and higher disease stage (p=0.004) were associated with FT. After adjustment, household income, employment status, and disease stage remained independently associated. Income was the strongest predictor, with a dose-response relationship (vs >$80,000: $40,000-80,000 aOR 4.16, 95% CI 1.43-12.12; <$40,000 aOR 6.19, 95% CI 1.64-23.33). Notably, 7% had considered forgoing treatment for financial reasons. Conclusions: Financial toxicity affected nearly half of the patients undergoing breast cancer surgery in the Canadian healthcare system, despite all patients having insurance coverage. Our findings highlight the role of social determinants of health in FT and identify low household income as a potentially pragmatic screening criterion for proactive mitigation strategies.